Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects
Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects
To investigate the pharmacokinetics of BAY1101042 in subjects with mild to severe renal
 impairment, stratified according to estimated glomerular filtration rate (eGFR) determined
 2-10 days prior to dosing, and age-, weight- and gender- matched healthy subjects and to
 assess the safety, tolerability, and pharmacodynamics of BAY1101042 after a single oral dose
 of a 10 mg BAY1101042 given as 5 mg modified release (MR) tablet.
Inclusion Criteria:

 -  Ability to understand and follow study-related instructions and ability to participate
 in the study for the entire period.

 -  Age: 18 to 79 years (inclusive) at the screening visit.

 -  Body mass index (BMI): 18 to 34 kg/m² (both inclusive).

 -  Male or female subject.

 -  Only women without childbearing potential will be included in the study (e.g.
 postmenopausal for at least one year, women with bilateral ovariectomy and women with
 hysterectomy).

 Subjects with renal impairment:

 -  eGFR <90 mL/min/1.73 m*2 determined from serum creatinine 2-10 days prior to dosing.

 -  Stable renal disease, i.e. a serum creatinine value determined at least 3 months
 before the pre-study visit (e.g. during routine diagnostics) should not vary by more
 than 20% from the serum creatinine value determined at the pre-study visit.

 Healthy subjects:

 - eGFR ≥90 mL/min/1.73 m*2 determined from serum creatinine 2-10 days prior to dosing.

 Exclusion Criteria:

 -  Pregnant or lactating women.

 -  Medical disorder, condition or history of such that would impair the subject's ability
 to participate or complete this study in the opinion of the investigator.